According to MBH Bank's analysis, the shares of the pharmaceutical company are significantly undervalued.Continue reading
Richter BioLogics GmbH & CoKG, the microbial biologics affiliate of Richter Gedeon, inaugurated a new state-of-the-art biotechnology plant in Bovenau, northern Germany, on September 13. The capacity expansion is one of the largest investments the Hungarian company has made in the last decade, writes the Richter’s portal.
“The commissioning of this facility is an important milestone in the implementation of Richter BioLogics’ growth strategy. With one of the largest investments for Richter in the last decade, we have become a key player in meeting global market demand and supplying the global pharmaceutical industry with the highest quality biotechnology products. We are also increasing our flexibility, one of our greatest and most valuable strengths,” emphasized Dr. Kai Pohlmeyer, Managing Director of Richter BioLogics.
The facility is equipped with the latest state-of-the-art technology for the clinical and large-scale production and market supply of protein- and plasmid DNA-based active pharmaceutical ingredients.
The total area of the multi-purpose facility has increased to around 10,000 square meters with the recent expansion: new 300 and 1,500 liter production lines provide additional flexibility for the simultaneous production of different products, allowing for the production of up to 120 batches per year, with additional areas being added for future growth. The facility also includes large laboratories for analytical tests, as well as warehouses and technical areas. By the end of 2024, the company plans to double the number of highly skilled local employees to over 400.
“This investment is both important for the future of Richter BioLogics, (…) and for Richter’s commitment to biologics, bringing these medicines to patients worldwide. In addition, we are a unique Hungarian company in that we are able to make significant, high value investments in Western Europe in an area with high added intellectual property value, meeting the highest quality standards. Our current biotechnology development fits into this line,” underlined Dr. Erik Bogsch, Head of the Biotechnology Business Unit at Richter Gedeon.
Budapest-based Richter Gedeon is one of the largest pharmaceutical companies in Central and Eastern Europe, having established a direct market presence in Western Europe, China, Latin America and Australia. With a market capitalization of EUR 4.3 billion at the end of 2023, the company achieved consolidated sales of around EUR 2.1 billion in the same year. The company’s product portfolio covers a number of important therapeutic areas – gynecological, central nervous system, cardiovascular. With the largest R&D center in Central and Eastern Europe, the company’s original research focuses on diseases of the central nervous system. With its widely recognized expertise in steroid chemistry, Richter is one of the world’s leading companies in the field of gynecology.
Via Richter Gedeon; Featured image via Hungary Today